SecProbe.io

Filing text and metadata
Intelligence Terminal Search Topics Monthly Activity About

Correspondence 0001104659-23-054339 from AVENUE THERAPEUTICS, INC. (ATXI) (CIK 0001644963) (ATXI)

AVENUE THERAPEUTICS, INC. (ATXI) (CIK 0001644963)
Date: May 1, 2023 · CIK: 0001644963 · Accession: 0001104659-23-054339

AI Filing Summary & Sentiment

File numbers found in text: 333-271208

Date
May 1, 2023
Author
Not clearly detected
Form
CORRESP
Company
AVENUE THERAPEUTICS, INC. (ATXI) (CIK 0001644963)

Letter

Avenue Therapeutics, Inc.

1111 Kane Concourse, Suite 301, Bay Harbor Islands, FL 33154

VIA EDGAR

May 1, 2023

Securities and Exchange Commission

Division of Corporation Finance

Office of Life Sciences

100 F Street, N.E.

Washington, D.C. 20549

Attn: Alan Campbell

Re: Avenue Therapeutics, Inc.

Registration Statement on Form S-1 (File. No. 333-271208)

Request for Acceleration of Effective Date

Ladies and Gentlemen:

Pursuant to Rule 461 under the Securities Act of 1933, as amended, Avenue Therapeutics, Inc. (the “Company”) hereby requests that the Securities and Exchange Commission (the “Commission”) accelerate the effective date of the above-referenced Registration Statement on Form S-1 (as amended, the “Registration Statement”) so that the Registration Statement will be declared effective as of 4:30 p.m. Eastern time, on May 3, 2023, or at such other time as the Company or its outside counsel, McGuireWoods LLP, may request via a telephone call to the staff of the Commission.

Once the Registration Statement has been declared effective, please orally confirm that event with David Wolpa of McGuireWoods at (704) 343-2185, or in his absence, Rakesh Gopalan of McGuireWoods LLP at (704) 343-2275.

Thank you for your assistance in this matter.

Sincerely,
Avenue Therapeutics, Inc.

Show Raw Text
CORRESP
1
filename1.htm

Avenue Therapeutics, Inc.

1111 Kane Concourse, Suite 301, Bay Harbor
Islands, FL 33154

VIA EDGAR

May 1, 2023

Securities and Exchange Commission

Division of Corporation Finance

Office of Life Sciences

100 F Street, N.E.

Washington, D.C. 20549

Attn: Alan Campbell

Re: Avenue Therapeutics, Inc.

  Registration Statement
on Form S-1 (File. No. 333-271208)

  Request for Acceleration of Effective Date

Ladies and Gentlemen:

Pursuant to Rule 461 under
the Securities Act of 1933, as amended, Avenue Therapeutics, Inc. (the “Company”) hereby requests that the Securities
and Exchange Commission (the “Commission”) accelerate the effective date of the above-referenced Registration Statement
on Form S-1 (as amended, the “Registration Statement”) so that the Registration Statement will be declared effective
as of 4:30 p.m. Eastern time, on May 3, 2023, or at such other time as the Company or its outside counsel, McGuireWoods LLP, may request
via a telephone call to the staff of the Commission.

Once the Registration Statement
has been declared effective, please orally confirm that event with David Wolpa of McGuireWoods at (704) 343-2185, or in his absence, Rakesh
Gopalan of McGuireWoods LLP at (704) 343-2275.

Thank you for your assistance
in this matter.

   Sincerely,

    Avenue Therapeutics, Inc.

    /s/ Alexandra MacLean

    Alexandra MacLean, Chief
Executive Officer